Di­ver­si­ty of Hu­mi­ra biosim­i­lar launch­es re­veals the dif­fi­cul­ty of de­thron­ing Ab­b­Vie's megablock­buster

San­doz, Boehringer In­gel­heim, Organon/Sam­sung and oth­ers are now tak­ing their shot at Ab­b­Vie’s megablock­buster Hu­mi­ra, with launch­es of their biosim­i­lars on Sat­ur­day, and myr­i­ad ap­proach­es to take mar­ket share that Ab­b­Vie has so far de­fend­ed well against.

Boehringer, which is the on­ly com­pa­ny with an in­ter­change­able biosim­i­lar on the mar­ket so far, con­firmed that the low­est-cost ver­sion of its in­ter­change­able won’t launch un­til next year, and the ver­sion that launched on Ju­ly 1 is priced with on­ly a slight dis­count to Hu­mi­ra.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER